文献速递脑血管病

SARS-CoV-2对卒中亚型、救治与死亡风险的Meta分析

The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis.
PubMed 文献 · Ann Neurol · 2020-12-09

该Meta分析纳入18项观察性队列研究、共67,845例患者,评估SARS-CoV-2感染与脑血管事件发生及结局的关系。合并结果显示,感染者缺血性卒中和隐源性卒中的风险升高,院内死亡风险亦升高;是否接受静脉溶栓或血管内取栓与感染状态无关。

要点

  • SARS-CoV-2感染者缺血性卒中风险升高(OR=3.58),隐源性卒中风险亦升高(OR=3.98)。
  • 感染者院内死亡风险显著升高(OR=5.60),需加强监护与二级预防。
  • 感染状态不影响静脉溶栓或血管内取栓的实施可能性。

核心结论

  • SARS-CoV-2感染可能与缺血性卒中风险升高相关,尤其隐源性卒中,并可能与死亡风险升高相关。

研究设计与样本

  • 系统综述与随机效应模型Meta分析,纳入18项报告脑血管事件发生和/或结局与SARS-CoV-2感染状态关系的观察性队列研究,共67,845例患者。

主要发现

  • SARS-CoV-2患者中因脑血管事件住院比例为1.3%(95%CI=0.9-1.6%,I2=87%)。
  • 缺血性卒中住院比例为1.1%(95%CI=0.8-1.3%,I2=85%),出血性卒中为0.2%(95%CI=0.1-0.3%,I2=64%)。
  • 与非感染同期或历史对照相比,感染者缺血性卒中风险升高(OR=3.58,95%CI=1.43-8.92,I2=43%),隐源性卒中风险升高(OR=3.98,95%CI=1.62-9.77,I2=0%)。
  • 感染者合并糖尿病比例高于非感染历史对照(OR=1.39,95%CI=1.00-1.94,I2=0%)。
  • 感染者院内死亡风险高于非感染同期或历史卒中患者(OR=5.60,95%CI=3.19-9.80,I2=45%)。

关键数值与推荐

  • 住院缺血性卒中患者中,SARS-CoV-2感染状态与接受静脉溶栓的可能性无关联(OR=1.42,95%CI=0.65-3.10,I2=0%)。
  • 住院缺血性卒中患者中,SARS-CoV-2感染状态与接受血管内取栓的可能性无关联(OR=0.78,95%CI=0.35-1.74,I2=0%)。

临床怎么用

  • 对SARS-CoV-2感染者应警惕缺血性卒中,尤其隐源性卒中的可能。
  • 感染者发生卒中后院内死亡风险较高,应加强监测与救治。
  • 不应因SARS-CoV-2感染状态而降低静脉溶栓或血管内取栓的评估意愿。

局限性

  • 纳入研究均为观察性队列,可能存在混杂与选择偏倚。
  • 部分合并结果异质性较高(如脑血管事件住院比例I2=87%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Emerging data indicate an increased risk of cerebrovascular events with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlight the potential impact of coronavirus disease (COVID-19) on the management and outcomes of acute stroke. We conducted a systematic review and meta-analysis to evaluate the aforementioned considerations. METHODS: We performed a meta-analysis of observational cohort studies reporting on the occurrence and/or outcomes of patients with cerebrovascular events in association with their SARS-CoV-2 infection status. We used a random-effects model. Summary estimates were reported as odds ratios (ORs) and corresponding 95% confidence intervals (CIs). RESULTS: We identified 18 cohort studies including 67,845 patients. Among patients with SARS-CoV-2, 1.3% (95% CI = 0.9-1.6%, I2 = 87%) were hospitalized for cerebrovascular events, 1.1% (95% CI = 0.8-1.3%, I2 = 85%) for ischemic stroke, and 0.2% (95% CI = 0.1-0.3%, I2 = 64%) for hemorrhagic stroke. Compared to noninfected contemporary or historical controls, patients with SARS-CoV-2 infection had increased odds of ischemic stroke (OR = 3.58, 95% CI = 1.43-8.92, I2 = 43%) and cryptogenic stroke (OR = 3.98, 95% CI = 1.62-9.77, I2 = 0%). Diabetes mellitus was found to be more prevalent among SARS-CoV-2 stroke patients compared to noninfected historical controls (OR = 1.39, 95% CI = 1.00-1.94, I2 = 0%). SARS-CoV-2 infection status was not associated with the likelihood of receiving intravenous thrombolysis (OR = 1.42, 95% CI = 0.65-3.10, I2 = 0%) or endovascular thrombectomy (OR = 0.78, 95% CI = 0.35-1.74, I2 = 0%) among hospitalized ischemic stroke patients during the COVID-19 pandemic. Odds of in-hospital mortality were higher among SARS-CoV-2 stroke patients compared to noninfected contemporary or historical stroke patients (OR = 5.60, 95% CI = 3.19-9.80, I2 = 45%). INTERPRETATION: SARS-CoV-2 appears to be associated with an increased risk of ischemic stroke, and potentially cryptogenic stroke in particular. It may also be related to an increased mortality risk. ANN NEUROL 2021;89:380-388.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Katsanos AH, Palaiodimou L, Zand R, et al. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis. Ann Neurol. 2020. PMID: 33219563. doi:10.1002/ana.25967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。